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Transcription factors that drive non-neoplastic myelomonocytic differentiation are well character-
ized but have not been systematically analyzed in the leukemic context. We investigated widely
used, patient-derived myeloid leukemia cell lines with proclivity for differentiation into granulo-
cytes by retinoic acid (RA) and/or monocytes by 1,25-dihyrdroxyvitamin D3 (D3). Using K562 (FAB
M1), HL60 (FAB M2), RA-resistant HL60 sublines, NB4 (FAB M3), and U937 (FAB M5), we correlated
nuclear transcription factor expression to immunophenotype, G1/G0 cell cycle arrest and functional
inducible oxidative metabolism. We found that myelomonocytic transcription factors are aberrantly
expressed in these cell lines. Monocytic-lineage factor EGR1 was not induced by D3 (the monocytic
inducer) but instead by RA (the granulocytic inducer) in lineage bipotent myeloblastic HL60. In
promyelocytic NB4 cells, EGR1 levels were increased by D3, while Gfi-1 expression (which promotes
the granulocytic lineage) was upregulated during D3-induced monocytic differentiation in HL60,
and by RA treatment in monocytic U937 cells. Furthermore, RARa and VDR expression were not
strongly correlated to differentiation. In response to different differentiation inducers, U937 exhib-
ited the most distinct transcription factor expression profile, while similarly mature NB4 and HL60
were better coupled. Overall, the differentiation induction agents RA and D3 elicited cell-specific
responses across these common FAB M1-M5 cell lines.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Differentiation induction therapy agents like all-trans retinoic
acid (RA) and 1,25-dihyrodxyvitamin D3 (D3) show promise in
many cancer cells types [1–3]. Although acute myeloid leukemias
(AML) are extremely heterogeneous diseases, with over 200 known
AML-related cytogenic aberrations [4], RA and D3 evoke compara-
ble responses in human myeloid leukemia cell lines, i.e. RA induces
granulocytic events while D3 induces monocytic events. WhetherRA and D3 can act additively, synergistically or antagonistically is
an outstanding question, since each behavior has been observed
in different contexts. Although lineage-determining myeloid tran-
scription factors are well characterized for the nonmalignant case
[5–7], systematic analysis of their expression during differentiation
induction therapy in leukemia is lacking. In this study we used
sequentially more mature, human myeloid leukemia cell lines
K562 (FAB M1), HL60 (FAB M2), NB4 (FAB M3) and U937 (FAB
M5) and compared treatment-induced expression of an ensemble
of well-known transcription factors that govern myelomonocytic
lineage selection.
K562 is a chronic myelogenous leukemia (CML) cell line (FAB
M1) that harbors the Bcr-Abl fusion protein [8,9]. K562 cells exhi-
bit inducible erythroleukemic and megakaryocytic characteristics
[10,11], but are not responsive to either RA [12,13] or D3 treatment
[14], and thus serve as a negative control for RA- or D3-induced
differentiation. HL60 leukemia cells are FAB M2 lineage-bipotent
myeloblasts [15,16] that can differentiate along either the granulo-
cytic lineage (using RA) or monocytic lineage (using D3). HL60 cells
are t(15;17)-negative, so RA-induced therapy must act through a
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described two sequentially emergent RA-resistant HL60 cell lines
that differ in their RA-inducible CD38 expression, termed R38+
and R38 [17,18]. These lines, which do not growth arrest or exhi-
bit other RA-induced markers when treated with RA, demonstrate
that as RA resistance becomes more profound, progressive resis-
tance to D3 also develops. NB4 is an acute promyelocytic leukemia
(APL) cell line (FAB M3) that does contain the t(15;17) transloca-
tion pathognomonic for APL [19–21]. NB4 cells are highly RA-
responsive, but are less responsive to D3 than wild-type HL60 cells
are, and require combination treatment to achieve any degree of
monocytic differentiation [22,23]. U937 monocytic leukemia cells
(FABM5), the most mature cells in this study, are highly responsive
to D3-induced monocytic/macrophage differentiation. RA exerts
ambiguous differentiative effects in U937, which at times have
been considered either monocytic or granulocytic [24–26]. U937
cells harbor a t(10;11) translocation, a recurrent event found in
AML cells and T cell acute lymphoblastic leukemia [4,27].
During non-neoplastic myelomonopoiesis, the transcription
factors PU.1 (a myeloid lineage master regulator) and C/EBPa have
positive effects on both granulocytic and monocytic maturation,
but the ratio of PU.1 to C/EBPa determines granulocytic versus
monocytic lineage selection [28]. This is due to a bistable switch
described by Laslo et al. (2006) [29] that involves mutually antag-
onistic repressors Gfi-1 and EGR1 which lie downstream of PU.1
and C/EBPa. Gfi-1 represses monocytic differentiation and pro-
motes granulocytic lineage selection, while EGR1 acts conversely.
In addition to retinoid acid receptor a (RARa) and vitamin D recep-
tor (VDR), other transcription factors found to be significant,
specifically to RA-induced differentiation, are IRF-1, AhR and
Oct4 [30,31]. Aryl hydrocarbon receptor (AhR) expression
increases during myeloid differentiation of HL60 [30] as well as
during monocytic differentiation of HL60 and U937 [32], and pro-
motes Oct4 downregulation, putatively relieving stemness. IRF-1
expression is induced by RA in HL60, NB4 and U937 cells [31,33],
but not K562 cells [34], and this expression appears to be Stat1-
independent [35].
In this study we treated K562, wild-type and RA-resistant HL60,
NB4 and U937 cells with RA, D3, or combination RA + D3 and
assessed differentiation using immunophenotypic markers CD38
and CD11b (myelomonocytic markers) and CD14 (a monocytic-
specific marker). Additionally we assessed G1/G0 cell cycle arrest
and inducible oxidative metabolism, a functional differentiation
marker of mature myelomonocytic cells. We surveyed nuclear
expression of the nine aforementioned transcription factors and
analyzed their coupling to cellular phenotype. Our intentions were
to: (1) provide ourselves and others with a comparative index of
responses by these cell lines, (2) identify departures from the norm
of myelomonocytic transcription factor expression in the leukemic
differentiation context, (3) determine how the transcription factor
expression and phenotypic marker signatures couple to the indi-
vidual treatments (RA, D3 or RA + D3) and to myeloid cell maturity,
and (4) determine if combined RA + D3 treatment promotes one
lineage over the other.
2. Materials and methods
2.1. Cell lines and treatments
Original HL60 patient isolates were a gift of Dr. Robert Gallagher
and maintained in this laboratory. Two retinoic acid (RA)-resistant
HL60 sublines (R38+ and R38) were isolated as described previ-
ously [17]. NB4 cells were provided by Ethan Dmitrovsky (Dart-
mouth University). American Type Cell Culture (ATCC)-obtained
U937 cells were provided by Tracy Stokol (Cornell University)and ATCC-obtained K562 cells were provided by Hening Lin (Cor-
nell University). No human primary tissues were obtained or used
in this study—all parent cell lines were established approximately
30 years ago [8,15,19,25] and are purchasable from ATCC. Cells
were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 5% (HL60) or 10% (K562, NB4, U937) heat-
inactivated fetal bovine serum (FBS; Hyclone, Logan, UT) and 1%
antibiotic–antimycotic (Invitrogen) and maintained in a 5% CO2
humidified environment at 37 C. Cells were seeded at either
0.1  106 cells/ml (HL60), 0.2  106 cells/ml (HL60, NB4, U937) or
0.3  106 cells/ml (K562). Cell viability consistently exceeded
95%. All-trans retinoic acid (RA; Sigma, St. Louis MO) was added
from a 5 mM stock solution in 100% ethanol to a final concentra-
tion of 1 lM in culture. 1,25-Dihydroxyvitamin D3 (D3; Cayman
Chemicals, Ann Arbor, MI) was added from a 1 mM stock solution
in 100% ethanol to a final concentration of 0.5 lM in culture.
2.2. Flow cytometry
CD surface markers were detected using anti-CD38 (PE), anti-
CD11b (APC) and anti-CD14 (PE) antibodies (BD Biosciences, San
Jose, CA). 0.5  106 cells were harvested and analyzed by flow
cytometry on a BD LSRII flow cytometer (BD Biosciences) as
described previously [18]. For cell cycle analysis, cells were har-
vested and stained with propidium iodide-containing solution
and analyzed as described previously [18]. For reactive oxygen spe-
cies quantification, cells were treated with 0.2 lg/ml 12-o-tetrade
canoylphorbol-13-acetate (TPA, Sigma, St. Louis, MO) or dimethyl
sulfoxide (DMSO) carrier and stained with 5 lM 5-(and-6)-chloro
methyl-20,70-dichlorodihydro–fluorescein diacetate acetyl ester
(H2-DCF, Molecular Probes, Eugene, OR), then analyzed by flow
cytometry as described previously [18].
2.3. Western blotting
Cell nuclear lysates were isolated using the NE-PER extraction
kit (Thermo Scientific, Rockford, IL). Equal amounts of protein
lysate (15 lg) were resolved by SDS–PAGE and transferred onto
PVDF membrane (Millipore, Billerica, MA). Blots were blocked
and incubated with primary and secondary antibody as described
previously [18]. Primary antibodies were specific against C/EBPa,
RARa, VDR, EGR1, PU.1, Oct4 (Cell Signaling, Danvers, MA), AhR,
Gfi-1 (Santa Cruz Biotechnology, Santa Cruz, CA) and IRF-1 (BD Bio-
sciences). Anti-Histone 3 or anti-TATA-binding protein (Cell Signal-
ing) were used to ensure even loading.
2.4. Statistical analysis
p-Values between treatment group means were calculated
using ANOVA within GraphPad software. Repeat Western blot data
were quantified using ImageJ. Pearson correlation coefficient cal-
culation and hierarchical clustering analysis (average linking
method) were performed in MATLAB or Cluster 3.0.
3. Results
3.1. Induced phenotypic changes in K562, HL60, NB4 and U937 cells
Wild-type and RA-resistant HL60 maintained in our laboratory
have a doubling time of approximately 20 h (Fig. 1A, B) and are
grown in RPMI 1640 medium with 5% FBS. We obtained K562,
NB4 and U937 cell lines which have slower doubling times and
are maintained in RPMI medium with 10% FBS (Fig. 1A, B). Com-
pared to untreated wild-type HL60, untreated NB4 and U937 are
more mature, having higher basal expression levels of CD38 and
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Fig. 1. Comparison of cell line characteristics. (A) Box-and-whisker plots of cell line doubling times when grown in RPMI 1640 with serum. (B) Mean doubling times of cell
lines. (C) CD38, CD11b and CD14 expression were analyzed by flow cytometry and shown as percent positive cells for each myeloid cell line compared to wild-type (WT)
HL60, the bipotent system. Percent positive shift was determined by setting the WT HL60 control to exclude 95% of the population peak. NB4 (p < 0.0001) and U937 (p < 0.05)
had significantly higher CD38 expression than WT HL60. All cell lines had similar CD11b expression levels when untreated, but K562 (p < 0.01) and U937 (p < 0.001) had
higher CD14 expression compared to WT HL60.
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expression than the HL60 cell lines.
We investigated the phenotypic changes that result from differ-
entiation induction therapy in the myeloid leukemia cell line
panel. CD38, CD11b and CD14 expression, G1/G0 cell cycle arrest,
and cell densities were assessed in wild-type and the two RA-
resistant HL60 cell lines after 24, 48, and 72 h of treatment with
either retinoic acid (RA), 1,25-dihydroxyvitamin D3 (D3), or combi-
nation (RA + D3). Wild-type HL60 cells display a strong response to
both RA and D3 (Fig. 2A, B), with D3 treatment resulting in greater
CD11b expression as well as CD14 expression, as reported previ-
ously [18]. Combined RA + D3 treatment further enhances G1/G0
arrest and CD11b expression compared to either individual treat-
ment. However, lower CD14 expression was observed with com-
bined RA + D3 compared to D3 alone. This may suggest that RA
has an antagonistic effect on this monocytic-specific marker.
Meanwhile RA-resistant cells lines R38+ and R38 do not respond
to RA, with the exception of RA-inducible CD38 expression in R38+
HL60, as previously reported for 48 h [17]. Both R38+ and R38 are
responsive to D3 treatment, displaying increased CD11b, CD14 and
G1/G0 arrest, with the sequentially emergent line R38 being less
responsive. Interestingly, unlike wild-type HL60, RA fails to reduce
the D3-induced CD14 expression in R38+ and R38 HL60.
In K562 cells, our negative phenotypic control, RA, D3 or com-
bined RA + D3 treatment do not induce any change in CD38,
CD11b or CD14 expression, G1/G0 arrest, or cell density after 24,
48 and 72 h (Fig. 3A,B). In contrast, NB4 cells are highly responsive
to RA treatment, which induced CD38 and CD11b expression, G1/
G0 arrest, and greatly reduced cell density over time. Interestingly,
minor CD14 expression is RA-inducible in NB4 cells. This effect has
been reported previously [36], and may be due to aberrant effects
of the PML-RARa fusion protein (see Section 4). D3 treatment of
NB4 cells does not significantly reduce cell density, but does inducecomparable levels of CD38, CD11b and CD14 surface markers. In
NB4, combined RA + D3 treatment enhanced the effect of either
individual inducer. U937 cells appeared to arrest in culture over
time, even without treatment (Fig. 3A). This may reflect the greater
maturity of this cell line. U937 cells display the strongest response
to D3 treatment compared to the other cell lines, with over 50%
CD14 expression occurring by 72 h in the D3 and RA + D3 treated
cases (Fig. 3A,B). Unlike wild-type HL60, combined RA treatment
fails to reduce the D3-induced CD14 expression in U937 cells.
However, RA enhances D3-induced CD38 and CD11b expression,
and RA alone can induce significant CD38 expression and very
minor CD11b expression in U937.
We also assessed reactive oxygen species (ROS) production, or
inducible oxidative metabolism in response to 12-o-tetradecanoyl
phorbol-13-acetate (TPA), which is a marker of functional differen-
tiation in mature myelomonocytic leukemia cells. RA and D3 sig-
nificantly increase ROS, with RA + D3 causing greater ROS
production compared to either inducer alone, in wild-type HL60
(Fig. 4). R38+ HL60 only exhibit TPA-induced ROS in the presence
of D3, and R38 only minimally during RA + D3 treatment. K562
are functionally unresponsive to RA or D3 induction, while NB4
display striking TPA-induced oxidative metabolism with RA treat-
ment. However, U937 had surprisingly low ROS production, with a
significant increase occurring only after the combined treatment.
For response to combined RA + D3 treatment, generally U937
and the RA-resistant HL60 lines R38+ and R38 were comparable
in that D3 induces monocytic changes that are only minimally
enhanced or unchanged by additional RA treatment. In wild-type
HL60, RA enhances D3 effects with the exception of CD14 expres-
sion, which is reduced. NB4 cells display a complex response, with
both RA and D3 inducing expression of CD38, CD11b and CD14 to
some extent. However in NB4 cells, cell density is greatly reduced
and functional oxidative metabolism is greatly enhanced only
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responses based on cell line identity and maturity can be compared
to the intracellular transcription factors expression profiles deter-
mined below.
3.2. Transcription factor expression in K562, HL60, NB4 and U937 cells
We surveyed nine transcription factors for their nuclear expres-
sion levels in the myeloid cell line ensemble treated with RA, D3 or
RA + D3 for 48 h. Nuclear RARa protein levels are unchanged in
treated HL60 (Fig. 5), which has been shown previously [18], but
in R38+ and R38 RA-resistant HL60 cells, RARa expression often
increased with treatments, whereas in the less mature K562 cells,treatment tends to decrease RARa. The more mature NB4 and to a
lesser extent U937 appear to exhibit RA-inducible nuclear RARa
expression which is blunted by combined RA + D3 treatment. In
contrast nuclear VDR expression is greatly enhanced whenever
D3 is present in every cell line, including phenotypically-
unresponsive K562 cells.
Nuclear PU.1 levels tend to be higher with RA treatment in
wild-type HL60 (Fig. 5). PU.1 expression is higher in U937 with
combined RA + D3 treatment, while expression is higher when
D3 is present in RA-resistant HL60. In NB4 cells, both RA- and com-
bined RA + D3-treated cells tend to have increased nuclear PU.1
expression, although D3 induced PU.1 expression as well. The C/
EBPa transcription factor could not be detected in K562. Nuclear
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HL60, R38+ HL60 and NB4. R38 and U937 are similar in their
expression of C/EBPa across treatments, which is highest for com-
bined RA + D3.
Nuclear Gfi-1 (which promotes granulocytic differentiation)
paradoxically increases during D3 treatment in wild-type HL60,
and is also higher in RA-treated U937 (Fig. 5). NB4 cells do not
exhibit RA-induced Gfi-1 upregulation, although Gfi-1 expression
decreases slightly with D3 treatment. Gfi-1 expression is more or
less unchanged in treated RA-resistant HL60 and was undetected
in K562. Strangely, nuclear EGR1 (which promotes monocytic dif-
ferentiation) expression is increased with D3 treatment alone in
NB4 cells, although combined RA + D3 suppresses EGR1 expression(Fig. 5). Meanwhile wild-type HL60 cells display increased EGR1
expression whenever exposed to RA. EGR1 expression is
unchanged in U937 and RA-resistant HL60, and may be slightly
decreased by all treatments in K562.
Nuclear IRF-1 is clearly induced by RA in the most RA-
responsive lines, wild-type HL60 and NB4 (Fig. 6). Interestingly,
IRF-1 expression is higher across all treatments in the RA-
resistant HL60, and not detectable in U937. Combined RA + D3
treatment could increase IRF-1 expression in K562. Nuclear AhR
levels decrease with treatments in wild-type HL60, but remain
more or less the same in all other cell lines, therefore nuclear
AhR expression alone did not reveal significant dependencies on
RA- versus D3-induced differentiation (Fig. 6). Nuclear Oct4
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Fig. 4. Inducible ROS production in wild-type HL60, R38+ HL60, R38 HL60, U937, K562 and NB4 cells at 72 h. Cells were stimulated with TPA to induce respiratory burst
activity. Percent positive cells were determined by flow cytometric detection of DCF fluorescence.
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reduced with treatments (Fig. 6), but quantified fold change results
were sensitive to small differences due to the faintness of the band.
Below, we address the importance of myeloid leukemia cell line
maturity versus differentiation-inducing agents by performing
clustering analyses on transcription factor expression and pheno-
type data.
3.3. Clustering of treated cell lines based on transcription factor
expression
Quantified 48 h nuclear transcription factor expression data
were subject to hierarchical clustering analysis. The simple antici-
pation was to observe clusters grouped by treatment rather than
by cell line, to indicate that the same treatment evokes a similar
response across all myeloid types. But contrary to this anticipation,
we found that the induced transcription factor response in U937
cells is highly divergent from all other cases, indicating a cell
line-specific expression pattern (Fig. 7A). However, all other mye-
loid leukemia cell lines treated with D3 (with the exception of
R38+) are grouped within a single subcluster. This could suggest
that for less mature cell lines, the identity of the inducer, rather
individual cell lines with distinct karyotypes, can take precedence
in determining transcription factor expression. Also included in
this cluster are the least RA-responsive lines, K562 and R38-, when
treated with combination RA + D3. But this cluster seemed to be
grouped based on VDR expression, which could be uncorrelated
from phenotypic maturation (as exemplified by K562 cells). R38+
HL60 and NB4 cells, respectively poor and good RA-responders,
are closely coupled based on similar treatments (RA alone or com-
bined RA + D3). However these also seemed to be grouped based
on a single transcription factor, IRF-1, rather than on a collectively
similar expression profile of several transcription factors. Finally,
RA-treated and combined RA + D3-treated wild-type HL60 are
grouped closely together but distal from the other strong RA
responder, NB4.
We repeated hierarchical clustering analysis after eliminating
VDR and IRF-1, which had very dominant (high) nuclear expression
levels and were poorly coupled to the transcription factor ensem-
ble. We also removed RARa from the analysis since RARa expres-
sion was found above to correspond poorly to RA response.Without these transcription factors, the highly non-responsive
K562 cells (treated and untreated) are then tightly grouped, while
the treated U937 cells remain in a highly coupled cluster (Fig. 7B).
This illustrates that differentiation induction agents result in very
cell line-specific transcription factor expression patterns in very
mature (U937) or very immature (K562) cells. Meanwhile cell lines
of closer maturity, NB4 (M3) and HL60 (M2), including the emer-
gent RA-resistant HL60 cell lines, are better clustered based on
treatment. RA-treated wild-type HL60 and NB4 cells are highly
coupled, as are D3-treated NB4 with RA + D3-treated wild-type
HL60. D3-treated wild-type and likewise D3-treated R38+ and
R38 HL60 cells are highly correlated. RA-treated R38+ and
R38 HL60 are clustered with the untreated cases.
3.4. Correlations between treatments, cell lines and transcription
factor expression
To identify couplings between nuclear transcription factor
expression and differentiation state (induced phenotypic shift),
we calculated correlation coefficient matrices between quantified
transcription factor expression and 48 h phenotypic marker data
across all six myeloid leukemia cell lines for RA treatment
(Fig. 7C), D3 treatment (Fig. 7D) and RA + D3 treatment (Fig. 7E).
We also assessed hierarchical clustering of phenotypic response
markers across all cell lines for RA treatment, D3 treatment and
RA + D3 treatment (Figs. 7F–H). Results did not indicate that RA
or D3 necessarily took precedence over the other agent during
combined treatment (see Section 4). For RA differentiation induc-
tion, CD38 expression, CD11b expression and ROS production are
more positively correlated with the transcription factor ensemble
compared to CD14 expression, G1/G0 arrest and cell culture den-
sity (Fig. 7C). For D3 differentiation induction, individual transcrip-
tion factors have very strong correlations (close to 1) with various
phenotypic responses, e.g. AhR or VDR with cell density and G1/G0
arrest, Gfi-1 or C/EBPa with CD14 expression, and PU.1, RARa or
IRF-1 with CD38 expression (Fig. 7D). Combined RA + D3 treatment
appears to result in a mixed phenotype, preserving some couplings
observed for both the RA and D3 treatment cases (Fig. 7E). For
example, VDR expression remains highly correlated to G1/G0
arrest while AhR expression is positively correlated to both CD38
and CD11b expression.
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lated in RA-treated cases (Fig. 7F). But G1/G0 groups with CD14
and cell density in a cluster distinct from CD38, CD11b, and ROS.
During D3 treatments, CD11b and CD14 are tightly coupled, and
better correlated to G1/G0 arrest and cell density (which were also
tightly coupled) than to CD38 or ROS production (Fig. 7G). Com-
bined RA + D3 treatment clustering is generally similar to RA (ver-
sus to D3) clustering, with CD14, G1/G0 arrest and cell density
grouped into the same cluster while CD11b is more highly corre-
lated with the cluster containing CD38 and ROS production
(Fig. 7H).4. Discussion
4.1. Impetus for cell line use and differentiation therapies
The limitations of monoculture and the divergence of continu-
ously passaged ex vivo cells from their original isolates [37] remain
valid concerns. However one study showed that several myeloid
cell lines, including K562, HL60, NB4, are faithful models of leuke-
mia [9]. Another group showed that compared to single cell lines,
panels of cell lines can at times better recapitulate features of
heterogeneous tissue populations [38]. Established cell lines
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mary cells or animal models, thus clarification of the characteris-
tics of broadly-employed cell lines like NB4 and U937 is of
significant value. Here we sought to examine the transcription fac-
tor expression profiles and their coupling to phenotypic state of a
panel of progressively mature myeloid leukemia cell lines.
Retinoic acid (RA) therapy induces remission in 80–90% of t
(15;17)-positive acute promyelocytic leukemia (APL) patients
[39], but has been limited by naïve/emergent RA resistance, cell-
type specific effects and limited understanding of the mechanism
of RA action. RA can exert its pro-differentiative and anti-
proliferative properties in breast, lung, kidney and prostate cancer
[1,2]. As a combination therapy, RA can be used to lower the
dosage of traditional chemotherapeutics or kinase inhibitors, or
when combined with other differentiation induction agents, miti-
gate the negative and augment the positive effects of the individual
inducers. For example, differentiation therapy using 1,25-
dihydroxyvitamin D3 (D3) has been less widespread since it can
induce hypercalcemia and hyperphosphatemia, but combination
with RA or use of D3 analogs [40,41] could reduce these side
effects.
4.2. Effects of RA and D3 treatment on their receptors and on
maturation in myeloid leukemia cell lines
RA and D3 act as ligand agonists for their cognate receptor/tran-
scription factors, retinoic acid receptors (RARs) and vitamin D
receptor (VDR), each of which can heterodimerize with retinoid
X receptor (RXR, whose ligand is 9-cis RA). Treatment with D3
increases the expression of VDR protein in HL60 [42], while RA
treatment results in a downregulation of VDR mRNA in HL60 [4]
and protein levels in K562, NB4, U937 and R38+ HL60 (this study).
However in KG1 cells, which are RA-responsive but not D3-
repsonsive, RA treatment actually induces upregulation of VDRmRNA [4]. Exposure of KG1 cells to both RA and D3 can thus rescue
expression of the monocytic marker CD14. Another FAB M2 cell
line, Kasumi-1, undergoes monocytic differentiation in response
to either D3 or RA [43]. Thus RA and D3 have differing effects on
expression of their cognate receptors in different myeloid lines.
There are also various crosstalk effects. Bastie et al. (2004) [44]
showed that in HL60 cells, D3 treatment (i.e. VDR) transrepresses
RA transcriptional activity, while RA does not transrepress D3.
However, we saw that combined RA + D3 treatment decreased
the D3-induced CD14 expression in HL60, which suggests the
opposite (i.e. RA inhibits D3 action). Meanwhile in NB4 cells the
opposite is true: D3 is not a transrepressor of RA transcriptional
activity, and RA treatment releases VDR and increases RARa bind-
ing to promoter regions [45]. Combined RA treatment can rescue
D3-induced differentiation in NB4 cells [23], but here we found
that D3 alone can induce several CD markers to some extent in
NB4. In fact, RA-induced CD14 expression in NB4 cells is known
[36], and several CD markers not expressed in RA-induced HL60
are expressed in RA-induced NB4, and vice versa [46]. This may
be directly related to the aberrant function of the PML-RARa fusion
protein which HL60 cells lack. Additionally, induced differentiation
of K562 (with compounds other than RA or D3) along the erythroid
and megakaryocytic lineages is accompanied by ambiguous
expression of CD markers for one or more lineages [11]. Since lin-
eage infidelity is a recurrent theme for induced leukemia, it is no
surprise to find that nuclear transcription factor expression devi-
ates from what is established for the nonmalignant case.
4.3. Aberrant transcription factor expression and cell-type versus
treatment-specific responses
The roles of transcription factors, especially PU.1 and C/EBPa, in
myelomonocytic lineage selection have been well characterized via
knockout, antisense and overexpression studies [5-7]. In this study,
Fig. 7. Clustering of cell line transcription factor profile and correlation of transcription factor to observed phenotype. (A) Average transcription factor expression matrix and
clustering of treated cell lines based on 48 h nuclear transcription factor expression data. Mean quantified Western blot data for each cell line treatment case was subject to
hierarchical clustering analysis using the Pearson correlation coefficient as a distance metric and using an average linking method. (B) Correlation and clustering without VDR,
IRF-1 or RARa. (C–E) Pearson correlation coefficient matrix between average transcription factor expression and phenotypic results at 48 h across all cell lines for (C) RA
treatments, (D) D3 treatments and (E) RA + D3 treatments. Hierarchical clustering of phenotypic results using average linkage for all cell lines across (F) RA treatments, (G) D3
treatments and (H) RA + D3 treatments.
H.A. Jensen et al. / FEBS Open Bio 5 (2015) 789–800 797the most salient result after surveying the nuclear expression of
several transcription factors was deviation from the mutually
antagonistic Gfi-1/EGR1 circuit [29]. HL60, NB4 and U937 leukemia
cells exhibit paradoxical effects compared to what has been
reported for Gfi-1 and EGR1, which promote granulocytic and
monocytic differentiation, respectively, in nonmalignantmyelomonocytic fate selection. In the most mature cell lines,
NB4 and U937, the treatment respective to each lines’ maturity
(RA for NB4 and D3 for U937) does not result in an increase in
the transcription factor that promotes that lineage (Gfi-1 is
unchanged with RA treatment in NB4, EGR1 is unchanged with
D3 treatment in U937). Oddly, treatment increases its correspond-
798 H.A. Jensen et al. / FEBS Open Bio 5 (2015) 789–800ing transcription factor in the cell line of the opposite lineage (RA
increases Gfi-1 expression in U937 and D3 increases EGR1 expres-
sion in NB4). We could speculate that lack of activation is prompt-
ing an increase in expression: Gfi-1 is not getting activated during
RA treatment in U937 cells, and EGR1 is not getting activated dur-
ing D3 treatment in NB4 cells, hence a compensatory expression
mechanism is being driven. Meanwhile in the bipotent HL60,
which are less mature, there is a different effect altogether. Treat-
ment instead drives expression of the transcription factor not cor-
responding to that lineage, i.e. D3 induces Gfi-1 expression and RA
induces EGR1 expression. This could again indicate that lack of
activation is prompting an increase in expression.
We compared the cell line transcription factor expression signa-
ture presented here to primary patient data curated from pub-
lished literature. While Gfi-1 overexpression is a known
characteristic in acute lymphoid leukemia, increased Gfi-1 expres-
sion can sometimes be detected in patients with chronic and acute
myeloid leukemias [47]. Additionally, Gfi-1 expression is low in
mature, end-stage granulocytes [47], which suggests that the lack
of increase in Gfi-1 expression after RA-induced differentiation in
NB4 and HL60 cells is not atypical. Also, Gfi-1 may actively repress
granulocytic genes in CD14+ monocytes [47], accounting for its
upregulation either by D3, or by RA in the monocytic cell line
U937. In the context of leukemia, EGR1 is generally known to have
a tumor suppressing function [48], which could explain its upreg-
ulation by D3 in NB4 cells, although not its lack of upregulation in
U937 cells. EGR1 expression is increased by RA in HL60 cells but, in
fresh AML patient samples, RA is known to reduce EGR1 expression
[49]. However, EGR1 acts as a tumor suppressor in cells with
deregulated c-Myc [48], which could account for its RA-induced
expression in the HL60 cell line. Freshly isolated cells from AML
patients have even higher constitutive VDR transcript expression
compared to established AML cell lines—VDR protein becomes pro-
tected from degradation when ligand is bound, and resistance
mechanisms typically occur downstream of the VDR protein [50].
This supports the consistent D3-induced VDR expression seen
across all cell lines in this study regardless of D3 responsiveness.
Meanwhile RARa expression is inducible by RA, but only in pri-
mary cells from AML M3 patients and perhaps not in other types
of AML [51]. This parallels our data where only the NB4 (FAB
M3) cell line tended to exhibit RA-inducible RARa expression.
One group found a correlation between increasing AML maturity
(M0-M5) and PU.1 expression levels with the exception of M3
(APL), which had very low PU.1 expression [52], and it is known
that RA treatment rescues PU.1 expression in primary APL cells
[53]. However in a study that examined 109 non-APL AML patient
samples, C/EBPa and PU.1 expression were both highly heteroge-
neous with a broad distribution across samples—expression could
be either much higher, similar to or much lower than that of non-
malignant granulocytes or monocytes [54]. Overall this highlights
that leukemias can exhibit extremely variable characteristics, with
individual cell lines being either capable or incapable of represent-
ing specific leukemias in patients. Cell lines can be used to repre-
sent a defined leukemia subset, or as stated previously, cell line
panels may be the mode d’emploi when comparing to patient
tissues.
We assessed whether a given agent evokes a similar response
across cell lines tested by investigating whether transcription fac-
tor expression profiles couple by treatment. We found results both
in favor and against this idea. We showed that there is a high cor-
relation between all D3-treated cell lines and RA + D3-treated
K562 and R38- (the least RA-responsive cell lines). This suggests
that the identity of the inducer, rather individual cell lines with
distinct karyotypes, can determine transcription factor expression.
Cell lines like NB4 and R38+ (respectively a good RA responder and
poor RA responder) could also be highly correlated based on thesame treatment pattern like RA alone or RA + D3 treatment. How-
ever, the importance of cell identity and maturity can still hold
sway as evidenced by U937 cells, which when treated with any
inducer were the least correlated from the remaining cases. Also,
clustering of treated cell lines appeared to associate strongly with
the expression of an individual transcription factor—rather than an
expression profile of several transcription factors—and these fac-
tors (i.e. VDR and IRF-1) were not significantly coupled to the
remaining factors. However, removal of VDR, IRF-1 and RARa from
the clustering analysis did not significantly skew the clustering
toward same-treatment groups.
We questioned whether induced myelomonocytic lineage
selection, during combined treatment with RA + D3, has a hierar-
chical differentiation relationship or solely a bifurcation struc-
ture. We previously found that progressive resistance to RA
also resulted in progressive resistance to D3, i.e. lineage induc-
tion occurred at the expense of the other lineage [18]. Comparing
correlations between transcription factor expression and pheno-
typic response across all cell lines for each treatment, RA + D3
treatment resulted in a mixed response with aspects from both
RA- and D3-induced differentiation (Fig. 7C). Figs. 7D–F suggest
that the RA + D3 phenotypic changes are more RA-like, and RA
+ D3 treatment enhances CD marker expression (including
CD14) in NB4 cells. However, in wild-type HL60, RA + D3 treat-
ment decreases CD14 expression compared to D3 alone, suggest-
ing that D3-induced signaling can be inhibited by RA-induced
signaling. Without nuclear VDR expression overpowering the
clustering analysis (Fig. 7B), D3-treated cases are separated
across different clusters. Reports in U937 cells have not truly
clarified whether RA enhances monocytic differentiation or pro-
motes granulocytic changes in these cells. While we found that
RA can induce certain changes interpretable as either granulo-
cytic or monocytic (CD38 expression, oxidative metabolism), RA
fails to upregulate the monocytic specific marker CD14 in U937
cells. Despite the distinctions between RA-induced granulocytic
or D3-induced monocytic lineage selection, the two pathways
exhibit a degree of crosstalk.
5. Conclusions
Although potent tools, cell lines must be employed with cir-
cumspection. We showed that transcription factor expression—
which is not a measure for activity—cannot be assumed similar
between nonmalignant lineage selection and corresponding
induced differentiation in leukemia cell lines. Additionally, a given
agent can elicit variable transcription factor expression across dif-
ferent myeloid cell lines. The most mature cell line U937 exhibited
transcription factor expression responses the most distinct from
the other cells, while more similarly mature cells like NB4 and
HL60 could be better coupled based on the same treatments. Gen-
erally combined RA + D3 treatment results in a mixed phenotype in
the responsive cell lines; however, cell line-specific effects remain,
e.g. RA potentiated D3-induced phenotypic changes in NB4 cells
but not in wild-type or RA-resistant HL60 cells.Authors contributions
Conceived and designed the experiments: HAJ. Performed the
experiments: HAJ, HBY. Analyzed the data: HAJ, HBY, RPB, AY. Con-
tributed reagents/materials/analysis tools: JDV, AY. Wrote the
paper: HAJ, RPB, JDV, AY.
Conflict of interest
The authors declare no conflict of interest.
H.A. Jensen et al. / FEBS Open Bio 5 (2015) 789–800 799Acknowledgements
NB4 cells were generously provided by David Sekula of Ethan
Dmitrovsky’s laboratory (Dartmouth University). U937 cells were
provided byWeeMing of Tracy Stokol’s laboratory (Cornell Univer-
sity), who obtained them from the ATCC. K562 cells were provided
by Jonathan Shrimp of Hening Lin’s laboratory (Cornell University),
who obtained them from the ATCC. This work was supported by
grants R01 CA033505, R01 CA152870 from NIH (A.Y.) and NIH/
PS-OC (Shuler/A.Y./R.P.B.), NYSTEM NY Dept. Health (A.Y.), Cornell
Vertebrate Genomics (VERGE) (R.P.B.), and CBET-0846876 from
NSF (J.D.V./H.A.J.).
References
[1] Bushue, N. and Wan, Y.Y. (2010) Retinoid pathway and cancer therapeutics.
Adv. Drug. Deliv. Rev. 62, 1285–1296.
[2] Tang, X. and Gudas, L.J. (2011) Retinoids, retinoic acid and cancer. Annu. Rev.
Pathol. Mech. 6, 345–364.
[3] Cheung, F.S., Lovicu, F.J. and Reichardt, J.K. (2012) Current progress in using
vitamin D and its analogs for cancer prevention and treatment. Expert Rev.
Anticancer Ther. 12 (6), 811–837.
[4] Gocek, E., Marchwicka, A., Baurska, H., Chrobak, A. and Marcinkowska, E.
(2012) Opposite regulation of vitamin D receptor by ATRA in AML cells
susceptible and resistant to vitamin D-induced differentiation. J. Steroid
Biochem Mol. Biol. 132 (3–5), 220–226.
[5] Tenen, D.G., Hromas, R., Licht, J.D. and Zhang, D.E. (1997) Transcription factors,
normal myeloid development, and leukemia. Blood 90 (2), 489–519.
[6] Rosenbauer, F. and Tenen, D.G. (2007) Transcription factors in myeloid
development: balancing differentiation with transformation. Nat. Rev.
Immunol. 7 (2), 105–117.
[7] Friedman, A.D. (2007) Transcriptional control of granulocyte and monocyte
development. Oncogene 26 (47), 6816–6828.
[8] Lozzio, C.B. and Lozzio, B.B. (1975) Human chronic myelogenous leukemia
cell-line with positive Philadelphia chromosome. Blood 45 (3), 321–334.
[9] Rücker, F.G., Sander, S., Döhner, K., Döhner, H., Pollack, J.R. and Bullinger, L.
(2006) Molecular profiling reveals myeloid leukemia cell lines to be faithful
model systems characterized by distinct genomic aberrations. Leukemia 20
(6), 994–1001.
[10] Andersson, L.C., Nilsson, K. and Gahmberg, C.G. (1979) K562–a human
erythroleukemic cell line. Int. J. Cancer 23 (2), 143–147.
[11] Sutherland, J.A., Turner, A.R., Mannoni, P., McGann, L.E. and Turc, J.M. (1986)
Differentiation of K562 leukemia cells along erythroid, macrophage, and
megakaryocyte lineages. J. Biol. Response Mod. 5 (3), 250–262.
[12] Koiso, Y., Nakajima, O., Matsumura, D., Fujimoto, Y. and Hashimoto, Y. (2000)
Chemical control of cell differentiation of human myeloleukemia K562 cell
line. Yakugaku Zasshi 120 (1), 104–112.
[13] Robertson, K.A., Mueller, L. and Collins, S.J. (1991) Retinoic acid receptors in
myeloid leukemia: characterization of receptors in retinoic acid-resistant K-
562 cells. Blood 77 (2), 340–347.
[14] Munker, R., Norman, A. and Koeffler, H. (1986) Vitamin D compounds. Effect
on clonal proliferation and differentiation of human myeloid cells. J. Clin.
Invest. 78, 424–430.
[15] Fontana, J.A., Colbert, D.A. and Deisseroth, A.B. (1981) Identification of a
population of bipotent stem cells in the HL-60 human promyelocytic leukemia
cell line. Proc. Natl. Acad. Sci. U.S.A. 78 (6), 3863–3866.
[16] Dalton, W.T., Ahearn, M.J., McCredie, K.B., Freireich, E.J., Stass, S.A. and Trujillo,
J.M. (1988) HL-60 cell line was derived from a patient with FAB-M2 and not
FAB-M3. Blood 71, 242–247.
[17] Jensen, H.A., Styskal, L.E., Tasseff, R., Bunaciu, R.P., Congleton, J., Varner, J.D.,
et al. (2013) The Src-family kinase inhibitor PP2 rescues inducible
differentiation events in emergent retinoic acid-resistant myeloblastic
leukemia cells. PLoS One 8 (3), e58621.
[18] Jensen, H.A., Bunaciu, R.P., Ibabao, C.N., Myers, R., Varner, J.D. and Yen, A.
(2014) Retinoic acid therapy resistance progresses from unilineage to
bilineage in HL-60 leukemic blasts. PLoS One 9 (6), e98929.
[19] Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F. and
Berger, R. (1991) NB4, a maturation inducible cell line with t(15;17) marker
isolated from a human acute promyelocytic leukemia (M3). Blood 77, 1080–
1086.
[20] Drexler, H.G., Quentmeier, H., MacLeod, R.A., Uphoff, C.C. and Hu, Z.B. (1995)
Leukemia cell lines: in vitro models for the study of acute promyelocytic
leukemia. Leuk. Res. 19 (10), 681–691.
[21] Gallagher, R.E. (2002) Retinoic acid resistance in acute promyelocytic
leukemia. Leukemia 16, 1940–1958.
[22] Bhatia, M., Kirkland, J.B. and Meckling-Gill, K.A. (1994) M-CSF and 1,25
Dihydroxyvitamin D3 synergize with 12-O-tetradecanoylphorbol-13-acetate
to induce macrophage differentiation in acute promyelocytic leukemia NB4
cells. Leukemia 8, 1744–1749.
[23] Testa, U., Grignani, F., Barberi, T., Fagioli, M., Masciulli, R., Ferrucci, P.F., et al.
(1994) PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restoresthe monocytic differentiation response to vitamin D3. Cancer Res. 54 (16),
4508–4515.
[24] Nakajima, H., Kizaki, M., Ueno, H., Muto, A., Takayama, N., Matsushita, H., et al.
(1996) All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-
induced monocytic differentiation of U937 cells. Leuk. Res. 20 (8), 665–676.
[25] Olsson, I.L. and Breitman, T.R. (1982) Induction of differentiation of the human
histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine
3’:5’-monophosphate-inducing agents. Cancer Res. 42 (10), 3924–3927.
[26] Defacque, H., Commes, T., Contet, V., Sevilla, C. and Marti, J. (1995)
Differentiation of U937 myelomonocytic cell line by all-trans retinoic acid
and 1,25-dihydroxyvitamin D3: synergistic effects on tissue transglutaminase.
Leukemia 9 (10), 1762–1767.
[27] Caudell, D. and Aplan, P.D. (2008) The role of CALM-AF10 gene fusion in acute
leukemia. Leukemia 22 (4), 678–685.
[28] Dahl, R., Walsh, J.C., Lancki, D., Laslo, P., Iyer, S.R., Singh, H., et al. (2003)
Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha
ratio and granulocyte colony-stimulating factor. Nat. Immunol. 4 (10), 1029–
1036.
[29] Laslo, P., Spooner, C.J., Warmflash, A., Lancki, D.W., Lee, H.J., Sciammas, R., et al.
(2006) Multilineage transcriptional priming and determination of alternate
hematopoietic cell fates. Cell 126, 755–766.
[30] Bunaciu, R.P. and Yen, A. (2011) Activation of the aryl hydrocarbon receptor
AhR promotes retinoic acid-induced differentiation of myeloblastic leukemia
cells by restricting expression of the stem cell transcription factor Oct4.
Cancer Res. 71, 2371–2380.
[31] Shen, M., Bunaciu, R.P., Congleton, J., Jensen, H.A., Sayam, L.G., Varner, J.D.,
et al. (2011) Interferon regulatory factor-1 binds c-Cbl, enhances mitogen
activated protein kinase signaling and promotes retinoic acid-induced
differentiation of HL-60 human myelo-monoblastic leukemia cells. Leuk.
Lymphoma 52, 2372–2379.
[32] Hayashi, S., Okabe-Kado, J., Honma, Y. and Kawajiri, K. (1995) Expression of Ah
receptor (TCDD receptor) during human monocytic differentiation.
Carcinogenesis 16 (6), 1403–1409.
[33] Matikainen, S., Ronni, T., Hurme, M., Pine, R. and Julkunen, I. (1996) Retinoic
acid activates interferon regulatory factor-1 gene expression in myeloid cells.
Blood 88 (1), 114–123.
[34] Grande, A., Montanari, M., Manfredini, R., Tagliafico, E., Zanocco-Marani, T.,
Trevisan, F., et al. (2001) A functionally active RARa nuclear receptor is
expressed in retinoic acid non responsive early myeloblastic cell lines. Cell
Death Differ. 8 (1), 70–82.
[35] Luo, X.M. and Ross, A.C. (2006) Retinoic acid exerts dual regulatory actions on
the expression and nuclear localization of interferon regulatory factor-1. Exp.
Biol. Med (Maywood) 231 (5), 619–631.
[36] Kim, D.Y., Choi, S.J., Kim, S.H., Chung, H.Y., Yi, S., Kim, D.W., et al. (2005)
Upregulated hoxC4 induces CD14 expression during the differentiation of
acute promyelocytic leukemia cells. Leuk. Lymphoma 46 (7), 1061–1066.
[37] Leupin, N., Kuhn, A., Hügli, B., Grob, T.J., Jaggi, R., Tobler, A., et al. (2006) Gene
expression profiling reveals consistent differences between clinical samples of
human leukaemias and their model cell lines. Br. J. Haematol. 135 (4), 520–
523.
[38] Domcke, S., Sinha, R., Levine, D.A., Sander, C. and Schultz, N. (2013) Evaluating
cell lines as tumour models by comparison of genomic profiles. Nat. Commun.
4, 2126.
[39] Tallman, M.S. and Altman, J.K. (2009) How I treat acute promyelocytic
leukemia. Blood 114 (25), 5126–5135.
[40] Zhou, J.Y., Norman, A.W., Akashi, M., Chen, D.L., Uskokovic, M.R., Aurrecoechea,
J.M., et al. (1991) Development of a novel 1,25(OH)2-vitamin D3 analog with
potent ability to induce HL-60 cell differentiation without modulating calcium
metabolism. Blood 78, 75–82.
[41] Rebel, V.I., Ossenkoppele, G.J., van de Loosdrecht, A.A., Wijermans, P.W.,
Beelen, R.H. and Langenhuijsen, M.M. (1992) Monocytic differentiation
induction of HL-60 cells by MC 903, a novel vitamin D analogue. Leuk. Res.
16, 443–451.
[42] Gocek, E., Kiełbin´ski, M. and Marcinkowska, E. (2007) Activation of
intracellular signaling pathways is necessary for an increase in VDR
expression and its nuclear translocation. FEBS Lett. 581, 1751–1757.
[43] Manfredini, R., Trevisan, F., Grande, A., Tagliafico, E., Montanari, M., Lemoli, R.,
et al. (1999) Induction of a functional vitamin D receptor in all-trans-retinoic
acid-induced monocytic differentiation of M2-type leukemic blast cells.
Cancer Res. 59 (15), 3803–3811.
[44] Bastie, J.N., Balitrand, N., Guidez, F., Guillemot, I., Larghero, J., Calabresse, C.,
et al. (2004) 1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid
transcriptional activity via vitamin D receptor in myeloid cells. Mol.
Endocrinol. 18 (11), 2685–2699.
[45] Bastie, J.N., Balitrand, N., Guillemot, I., Chomienne, C. and Delva, L. (2005)
Cooperative action of 1alpha, 25-dihydroxyvitamin D3 and retinoic acid in
NB4 acute promyelocytic leukemia cell differentiation is transcriptionally
controlled. Exp. Cell Res. 310 (2), 319–330.
[46] Barber, N., Belov, L. and Christopherson, R.I. (2008) All-trans retinoic acid
induces different immunophenotypic changes on human HL60 and NB4
myeloid leukaemias. Leuk. Res. 32 (2), 315–322.
[47] van der Meer, L.T., Jansen, J.H. and van der Reijden, B.A. (2010) Gfi1 and Gfi1b:
key regulators of hematopoiesis. Leukemia 24 (11), 1834–1843.
[48] Gibbs, J.D., Liebermann, D.A. and Hoffman, B. (2008) Leukemia suppressor
function of Egr-1 is dependent on transforming oncogene. Leukemia 22 (10),
1909–1916.
800 H.A. Jensen et al. / FEBS Open Bio 5 (2015) 789–800[49] Tokura, Y., Shikami, M., Miwa, H., Watarai, M., Sugamura, K., Wakabayashi, M.,
et al. (2002) Augmented expression of P-gp/multi-drug resistance gene by all-
trans retinoic acid in monocytic leukemic cells. Leuk Res. 26 (1), 29–36.
[50] Gocek, E., Baurska, H., Marchwicka, A. and Marcinkowska, E. (2012) Regulation
of leukemic cell differentiation through the vitamin D receptor at the levels of
intracellular signal transduction, gene transcription, and protein trafficking
and stability. Leuk. Res. Treat. 2012, 713243.
[51] Chomienne, C., Balitrand, N., Ballerini, P., Castaigne, S., de The, H. and Degos, L.
(1991) All-trans retinoic acid modulates the retinoic acid receptor-alpha in
promyelocytic cells. J. Clin. Invest. 88, 2150.[52] Zhu, X., Zhang, H., Qian, M., Zhao, X., Yang, W., Wang, P., et al. (2012) The
significance of low PU.1 expression in patients with acute promyelocytic
leukemia. J. Hematol. Oncol. 5, 22.
[53] Mueller, B.U., Pabst, T., Fos, J., Petkovic, V., Fey, M.F., Asou, N., et al. (2006)
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by
restoring PU.1 expression. Blood 107 (8), 3330–3338.
[54] D’Alò, F., Di Ruscio, A., Guidi, F., Fabiani, E., Greco, M., Rumi, C., et al. (2008)
PU.1 and CEBPA expression in acute myeloid leukemia. Leuk. Res. 32 (9),
1448–1453.
